Aging Immune System Program
Immunosenescence
Pre-clinicalActive
Key Facts
About NewLimit
NewLimit is a private, pre-clinical stage biotech focused on epigenetic reprogramming to combat aging and age-related diseases. The company is building a technology platform that integrates advanced genomics and machine learning to identify and develop therapies that can reset cellular age, starting with programs targeting the aging liver, immune, and vascular systems. Backed by prominent venture capital firms and strategic investors like Eli Lilly, NewLimit operates with a mission-driven, iterative R&D model aimed at translating fundamental biology into transformative medicines.
View full company profile